The B Lymphocyte Antigen CD20 pipeline drugs market research report outlays comprehensive information on the B Lymphocyte Antigen CD20 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the B Lymphocyte Antigen CD20 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Central Nervous System, and Genito Urinary System which include the indications Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis (RRMS), Kidney Disease (Nephropathy), and Membranous Glomerulonephritis. It also reviews key players involved in B Lymphocyte Antigen CD20 targeted therapeutics development with respective active and dormant or discontinued products.
The B Lymphocyte Antigen CD20 pipeline targets constitutes close to 106 molecules. Out of which, approximately 90 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 1, 10, 12, 17, 1, 3, 31, and 11 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical, and Discovery comprises 4, 9, 2, and 1 molecule.
B Lymphocyte Antigen CD20 overview
B-lymphocyte antigen CD20 is a specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Alternative splicing of this gene results in two transcript variants that encode the same protein.
For a complete picture of B Lymphocyte Antigen CD20’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
